ARMP

ARMP 简况

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using bacteriophage-based technology. The Company is a developer of synthetic phage platform, which targets therapeutics for the treatment of various multidrug-resistant bacterial infections. It develops synthetic phage products that target a specific pathogen begins with the isolation of natural phages from environmental and clinical samples. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AP-PA02 and AP-SA02.